Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (670)	9/1/1999 2:01:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

I think I have the answer: Although I only have access to the abstracts at PNAS, I do not see Wilson on the GvH paper from a year ago...so my guess is that the GvH product does not use a Genovo vector: Vol. 95, Issue 18, 10437-10442, September 1, 1998 Biochemistry Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity Tim Clackson*, Wu Yang, Leonard W. Rozamus, Marcos Hatada, Jane F. Amara, Carl T. Rollins, Lauren F. Stevenson, Shannon R. Magari, Susan A. Wood, Nancy L. Courage, Xiaode Lu, Franklin Cerasoli Jr., Michael Gilman, and Dennis A. Holt _____________________________________________ Okay...what will be my next question? Maybe something other than ARGENT for a change. How about something along these lines: Why does Schreiber's lab at Harvard seem to focus on SH3, while Ariad mentions SH2 domains. Maybe Ariad and Harvard have a close relationship and they've split up the work? Or is "Src homology region 3" more interesting than SH2. Newbies can see Molecular Biology of the Cell, Alberts et al...I have the third edition, page 762 has a little on SH2/SH3--it is in the chapter about cell signaling. Nearly all of it sails way over my head, and truth is, over my long weekend I read a novel and parts of the cancer chapter instead of re-reading chapter 15 like I said I would do over on Yahoo. Besides--I'm question man, not the answer man--I can get a feel for this stuff as slowly as I want to. ARIA: Bid is down below 85 cents--looks like there will be more shares now--just as the annual report suggested at the top of page 28. "If the conversion price fell even further, then more than 5,933,362 shares of common stock would be issuable upon conversion of the series C preferred stock. In addition, subject to certain conditions, we may be required during the month of September 1999 to sell additional shares of series C preferred stock at the then current market price and then applicable conversion prices to the original purchasers of series C preferred stock." Wont be long now before I'm stopped out, my loss on paper at 3/4ths will be something like 1/2 times 70k shares, ouch, cant be too happy about that. The game is almost over! That's okay, the stock market eats newbies like me for breakfast. Taking an interest in anything and loading up on shares is just damn foolish, I deserve these losses for being so naive. Lesson learned, it's all bullshit-- except the science of course, but science doesn't seem to move stocks.